The biotech will now take atebimetinib to mid- and late-stage trials in NSCLC and pancreatic cancer, respectively.

High levels of IB6 are often found in NSCLC, making it a good target for treatment. A preclinical study found that in lung cancer, IB6 was correlated with interleukin-8 levels and promoted cancer cell ...

Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its ...

Researchers have identified the mechanism by which cancer cells create their own growth signals to proliferate, independent ...

Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in ...